Dr. Reddy’s Laboratories on Saturday launched Obeda, a generic version of semaglutide for Type 2 diabetes, becoming the first Indian company to receive approval from the Drugs Controller General of India (DCGI) for the drug. This launch marks the company’s entry into the GLP-1 receptor agonist therapy segment immediately after patent expiry.
Dosage and Pricing
Obeda is available in 2 mg and 4 mg strengths in a pre-filled disposable pen for once-a-week subcutaneous use. Each pen provides four weekly doses, with the therapy priced at ₹4,200 per month for both strengths.
Clinical Evidence and Safety
In a Phase III study of 312 participants, Obeda demonstrated comparable efficacy and safety to the innovator drug, showing similar results in glycaemic control and related measures. The company developed and manufactured the drug entirely in-house, including the active pharmaceutical ingredient and formulation.
Global Plans and Strategy
Dr. Reddy’s plans to introduce generic semaglutide in multiple countries, subject to regulatory approvals. Erez Israeli said the launch reflects the company’s commitment to expanding its portfolio in critical therapeutic areas and highlights its expertise in complex product development and peptide science.
Focus on Quality and Expansion
Israeli added that through a “One Product, One Quality” approach, the company aims to ensure consistent, high-quality products across all markets while gradually expanding the availability of generic semaglutide internationally.
